Reports on PharmaPoint: Epilepsy - Drug Forecast and Market Analysis to 2022 for U.S., U.K., France, Germany, Italy, Spain, China & Japan added at ReportsnReports.com store.
Dallas, Texas (PRWEB) February 21, 2013
PharmaPoint: Epilepsy - US Drug Forecast and Market Analysis to 2022- The main drivers for growth in this market includes the launch of new AEDs with novel MOAs; healthcare reform, which will increase treatment rates; and a also growing elderly population with twice the risk of developing epilepsy.
PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022 - The main driver for growth in this market is the launch of new AEDs and the continued uptake of recent AEDs, although this is affected by government pricing and reimbursement regulations.
PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022- The main driver for growth in this market is the launch of new AEDs with novel MOAs and the lower-than-average rate of generic substitution in France compared with other countries, although this may change during the forecast period due to government cost-cutting strategies.
PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis to 2022 - The main factor for the decline in this market is the launch of generics and the high rate of generic substitution in Germany. In addition, strict government pricing restrictions will limit the pricing and penetration of new AEDs and will hamper the growth of the market in Germany.
PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to 2022- The main driver for growth in this market is the launch of new AEDs, the continued uptake of recent AEDs, and the lower-than-average rate of generic substitution in Italy compared with other countries, although this may change during the forecast period due to government cost-cutting strategies.
PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022 - The main drivers for growth in this market are the launch of new AEDs, the continued uptake of recent AEDs, and the lower-than-average rate of generic substitution in Spain compared with other countries, although this may change during the forecast period due to government cost-cutting strategies.
PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to 2022- Due to Chinas vast general population, which drives the growth of the prevalent population of epilepsy patients, the AED market is fairly large, despite the relatively low cost of treatment. The main driver for growth in this market will be the continued uptake of recent AEDs, a growing middle class with better healthcare access, and increased epilepsy treatment in the whole population due to government efforts to increase healthcare access. However, loose government regulation of patent protection, as well as a reliance on traditional Eastern medicine, severely impact brand drug penetration and profitability in China.
PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022- The main driver for growth in this market will be the launch of new AEDs (Vimpat and Banzel), the continued uptake of recent AEDs (Lamictal, Keppra, and Topina [topiramate]), and the lower-than-average rate of generic substitution in Japan compared with other countries. Government regulations on drug approval and pricing, however, limit or delay drug entry and profitability Japan.
Read the rest here:
Epilepsy Drugs Market: Analysis & Forecast 2022 for U.S., U.K., France, Germany, Italy, Spain, China & Japan in New ...